Home » Oxford Expression Tech, Eden Biodesign Form Co-marketing Pact

Oxford Expression Tech, Eden Biodesign Form Co-marketing Pact

Feb 02, 2009

NEW YORK (GenomeWeb News) — Oxford Expression Technologies and Eden Biodesign have struck a co-marketing agreement to serve pharmaceutical researchers involved in protein expression.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Articles

Jul 24, 2014

Agilent, MRM Proteomics Extend Co-marketing Agreement

Apr 29, 2014

InDevR, Applied Microarrays Partner to Deliver Custom Array Offering

Jun 12, 2014

ASU's Biodesign Institute Enters Phase Two of Radiation Dosimeter Project Using Life Tech Platform

Premium
Jul 01, 2014

Eurofins, AmpTec to Co-market Synthetic RNAs

May 09, 2014

Fluidigm Continues Push into Proteomics Despite Soft Q1 CyTOF Sales

Premium
May 13, 2014

American Pathology Partners to Promote MDxHealth Test

The Scan

Ancient Wheat

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

'High School Never Ends'

Joel Achenbach explores at National Geographic why people find science difficult to believe.

This Week in Science

In Science this week: gene linked to expansion of the human neocortex, and more.

Bit of an Increase

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Mar
05
Featured Webinar

Integrating Metabolomic and Proteomic Profiles for 'Less Impersonal' Medicine

Sponsored by
SomaLogic

In this live webcast, Robert Gerszten of Massachusetts General Hospital will describe an ongoing project that is integrating metabolic and proteomic profiling to gain a better understanding of cardiometabolic disease.

What's Popular?

In Proteomics & Protein Research

  1. Caprioli Lab Develops Approach to Integrate Imaging Mass Spec, Optical Microscopy Data

    Premium

  2. CPTAC Researchers Examine Development, Feasibility of Highly Multiplexed MRM-MS Assays

  3. Zyomyx Co-founder Steffen Nock Calls California Home -- For Now

    Premium

  4. Bruker and Bruker Intend to Merge, Joining Mass Spec, X-Ray Technology

    Premium

  5. Q&A: LabCorp's Russell Grant on the Challenges Facing Clinical Mass Spec

    Premium

Sponsorships

Privacy Policy.  Copyright © 2015 Genomeweb LLC.  All Rights Reserved.